M&T Bank’s Rigel Pharmaceuticals RIGL Stock Holding History

M&T Bank’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-1,156	Closed	-$23K	–	2224
2014 Q3	$23K	Buy	+1,156	New	+$32.7K	﹤0.01%	2149

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

M&T Bank's RIGL Position: Q4 2014 in Review

M&T Bank sold out of Rigel Pharmaceuticals (RIGL) in Q4 2014, closing a stake of 1,156 shares — an estimated $23K sold.

M&T Bank first reported a position in RIGL in Q3 2014 and held it in 1 quarter. The position peaked at $23K in Q3 2014. 96 funds tracked by Wall St. Rank hold RIGL as of Q4 2014.

M&T Bank reported no remaining Rigel Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
M&T Bank sold 1,156 Rigel Pharmaceuticals shares in Q4 2014, an estimated $23K.
M&T Bank first reported a position in Rigel Pharmaceuticals in Q3 2014 and held it in 1 quarter.
M&T Bank's Rigel Pharmaceuticals position peaked at $23K in Q3 2014.
96 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2014.

Based on M&T Bank's 13F filing for Q4 2014, filed 12 Feb 2015.